Lynx1 Capital Management LP T Scan Therapeutics, Inc. Transaction History
Lynx1 Capital Management LP
- $338 Million
- Q2 2025
A detailed history of Lynx1 Capital Management LP transactions in T Scan Therapeutics, Inc. stock. As of the latest transaction made, Lynx1 Capital Management LP holds 7,857,347 shares of TCRX stock, worth $13.1 Million. This represents 3.37% of its overall portfolio holdings.
Number of Shares
7,857,347
Previous 5,357,347
46.66%
Holding current value
$13.1 Million
Previous $7.39 Million
54.11%
% of portfolio
3.37%
Previous 2.73%
Shares
5 transactions
Others Institutions Holding TCRX
# of Institutions
80Shares Held
37.8MCall Options Held
0Put Options Held
0-
Bvf Inc San Francisco, CA5.23MShares$8.73 Million0.3% of portfolio
-
Black Rock Inc. New York, NY4.46MShares$7.45 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY2.78MShares$4.65 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.15MShares$3.59 Million0.0% of portfolio
-
Propel Bio Management, LLC Los Angeles, CA2.09MShares$3.49 Million3.67% of portfolio
About TScan Therapeutics, Inc.
- Ticker TCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,929,800
- Market Cap $31.6M
- Description
- TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...